Decoy Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statement of Stockholders' Equity
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Total Stockholders' Equity (Deficit) | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance at December 31, 2022 | 281,987 | $28 | $74,189,728 | $(63,805,148) | $10,384,608 |
| Issuance of equity securities, net | 201,580 | 20 | 6,920,509 | — | 6,920,529 |
| Equity-based compensation expense | 8,737 | 1 | 524,837 | — | 524,838 |
| Net loss | — | — | — | (12,542,693) | (12,542,693) |
| Balance at December 31, 2023 | 492,304 | $49 | $81,635,074 | $(76,347,841) | $5,287,282 |
| Issuance of equity securities, net | 948,853 | 95 | 1,526,365 | — | 1,526,460 |
| Equity-based compensation expense | — | — | 273,730 | — | 273,730 |
| Net loss | — | — | — | (5,575,777) | (5,575,777) |
| Balance at December 31, 2024 | 1,441,157 | $144 | $83,435,169 | $(81,923,618) | $1,511,695 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.